Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy

Michael Gabriel, Bernhard Nilica, Bernhard Kaiser and Irene J. Virgolini
Journal of Nuclear Medicine April 2019, 60 (4) 524-529; DOI: https://doi.org/10.2967/jnumed.118.215376
Michael Gabriel
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
2Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard Nilica
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard Kaiser
2Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irene J. Virgolini
1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 60 no. 4 524-529
DOI 
https://doi.org/10.2967/jnumed.118.215376
PubMed 
30115690

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 29, 2018
  • Accepted for publication August 10, 2018
  • Published online April 1, 2019.

Article Versions

  • previous version (August 16, 2018 - 11:37).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Michael Gabriel1,2,
  2. Bernhard Nilica1,
  3. Bernhard Kaiser2 and
  4. Irene J. Virgolini1
  1. 1Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria; and
  2. 2Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria
  1. For correspondence contact: Michael Gabriel, Department of Nuclear Medicine, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. E-mail: michael.gabriel{at}kepleruniklinikum.at
View Full Text

Statistics from Altmetric.com

Cited By...

  • 31 Citations
  • 32 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
    Romain Eychenne, Christelle Bouvry, Mickael Bourgeois, Pascal Loyer, Eric Benoist, Nicolas Lepareur
    Molecules 2020 25 17
  • Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
    Sangeeta Ray Banerjee, Il Minn, Vivek Kumar, Anders Josefsson, Ala Lisok, Mary Brummet, Jian Chen, Ana P. Kiess, Kwamena Baidoo, Cory Brayton, Ronnie C. Mease, Martin Brechbiel, George Sgouros, Robert F. Hobbs, Martin G. Pomper
    Journal of Nuclear Medicine 2020 61 1
  • Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy
    Mohamad Bassam Sonbol, Thorvardur R. Halfdanarson, Talal Hilal
    JAMA Oncology 2020 6 7
  • <p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>
    Jason S Starr, Mohamad Bassam Sonbol, Timothy J Hobday, Akash Sharma, Ayse Tuba Kendi, Thorvardur R Halfdanarson
    OncoTargets and Therapy 2020 Volume 13
  • Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors
    Solène Dermine, Lola-Jade Palmieri, Julie Lavolé, Amélie Barré, Antony Dohan, Einas Abou Ali, Anne-Ségolène Cottereau, Sébastien Gaujoux, Catherine Brezault, Stanislas Chaussade, Romain Coriat
    Journal of Clinical Medicine 2019 8 11
  • PRRT: identikit of the perfect patient
    M. Albertelli, A. Dotto, C. Di Dato, P. Malandrino, R. Modica, A. Versari, A. Colao, D. Ferone, A. Faggiano
    Reviews in Endocrine and Metabolic Disorders 2021 22 3
  • Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Sarit T. Kipnis, Matthew Hung, Shria Kumar, Jason M. Heckert, Hwan Lee, Bonita Bennett, Michael C. Soulen, Daniel A. Pryma, David A. Mankoff, David C. Metz, Jennifer R. Eads, Bryson W. Katona
    JAMA Network Open 2021 4 3
  • Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy
    Kim R. Kennedy, John Harvey Turner, William B. G. MacDonald, Phillip G. Claringbold, Glenn Boardman, David T. Ransom
    Cancer 2022 128 11
  • Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
    Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa
    Clinical and Translational Radiation Oncology 2020 22
  • Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
    Katherine I. Wolf, Abhishek Jha, Anouk van Berkel, Damian Wild, Ingo Janssen, Corina M. Millo, M. J. R. Janssen, Melissa K. Gonzales, Henri J. K. M. Timmers, Karel Pacak
    Nuclear Medicine and Molecular Imaging 2019 53 3

Article usage

Article usage: August 2018 to April 2025

AbstractFullPdf
Aug 2018370062
Sep 2018305031
Oct 2018194036
Nov 2018212011
Dec 2018150012
Jan 2019124021
Feb 2019183039
Mar 2019234049
Apr 2019145275218
May 201993833143
Jun 2019347765
Jul 2019267263
Aug 2019261784
Sep 2019166955
Oct 20192033493
Nov 2019173973
Dec 20191461556
Jan 20201863371
Feb 20201751980
Mar 20201183371
Apr 20201341843
May 20201842152
Jun 20201151154
Jul 2020951154
Aug 20201272146
Sep 20201012138
Oct 2020711937
Nov 202087846
Dec 2020862127
Jan 2021236546
Feb 2021757462
Mar 2021418739
Apr 2021256224
May 2021255631
Jun 2021266219
Jul 2021195923
Aug 2021225323
Sep 2021296741
Oct 2021125940
Nov 2021245550
Dec 2021135126
Jan 2022155531
Feb 2022136422
Mar 2022148530
Apr 2022136424
May 20221110314
Jun 2022412126
Jul 2022121326
Aug 2022105916
Sep 202249316
Oct 2022127820
Nov 2022610012
Dec 202296210
Jan 2023712614
Feb 2023512017
Mar 2023128412
Apr 202375113
May 202386520
Jun 202388119
Jul 202397418
Aug 202378014
Sep 202367915
Oct 202379214
Nov 2023211911
Dec 20232908
Jan 2024616418
Feb 202421326
Mar 2024914145
Apr 2024212730
May 2024417513
Jun 2024518222
Jul 2024618019
Aug 2024516520
Sep 2024525617
Oct 2024426129
Nov 202452068
Dec 202452608
Jan 2025222942
Feb 20251228115
Mar 2025226633
Apr 20251231435
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (4)
Journal of Nuclear Medicine
Vol. 60, Issue 4
April 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
Michael Gabriel, Bernhard Nilica, Bernhard Kaiser, Irene J. Virgolini
Journal of Nuclear Medicine Apr 2019, 60 (4) 524-529; DOI: 10.2967/jnumed.118.215376

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy
Michael Gabriel, Bernhard Nilica, Bernhard Kaiser, Irene J. Virgolini
Journal of Nuclear Medicine Apr 2019, 60 (4) 524-529; DOI: 10.2967/jnumed.118.215376
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • The Future of Health Care and the Importance of the Nuclear Medicine Technologist
  • Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionucleotide therapy
  • Preclinical Evaluation of 203/212Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer
  • Google Scholar

More in this TOC Section

Theranostics

  • Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Clinical

  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
  • SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
Show more Clinical

Similar Articles

Keywords

  • peptide receptor radionuclide therapy
  • somatostatin analogs
  • neuroendocrine tumors
  • radiopharmaceutical
  • individualized therapy
  • long-term follow-up
SNMMI

© 2025 SNMMI

Powered by HighWire